Industry

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Aura to Host Virtual Investor Day at 11:30 a.m. Eastern Time BOSTON–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC … [Read more…]

Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study

PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I/II clinical study utilizing Seneca Valley Virus (“SVV-001”) in combination with a checkpoint inhibitor. This Phase I/II study with SVV-001 is in patients … [Read more…]

Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

– Villaris shareholders to receive upfront payment of $70 million, with potential for up to $1.36 billion in additional milestone payments – Pre-clinical data for auremolimab demonstrate high potency, selectivity and efficacy in vitiligo – Acquisition will complement Incyte’s existing Inflammation and AutoImmunity portfolio with potential applications for auremolimab beyond Dermatology WILMINGTON, Del.–(BUSINESS WIRE)–$INCY–Incyte (NASDAQ:INCY) … [Read more…]

Global Sleep Apnea Device Market Report 2022: Increasing Demand for Remote Monitoring and Home Care to Drive Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Sleep Apnea Device Market Research and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global sleep apnea device market is growing at a considerable CAGR of 7.8% during the forecast period. Increasing pervasiveness of cardiovascular diseases and growing innovation and development of new products are estimated to be the prime … [Read more…]

Global Glaucoma Treatment Market Report 2022: Featuring Pfizer, F. Hoffmann-La Roche, Merck, Allergan & Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Glaucoma treatment Market Research and Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global glaucoma treatment market is anticipated to grow at a considerable CAGR of 5.2% during the forecast period (2021-2027). Glaucoma is one of the major eye disorders which causes damage to the optic nerve and can cause … [Read more…]

Global Glycomics Market Report 2022: Growing Research Activities in Glycomics Fueling Sector Expansion – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Glycomics Market – Forecasts from 2022 to 2027” report has been added to ResearchAndMarkets.com’s offering. The Glycomics Market is evaluated at US$1,174.889 million for the year 2022, growing at a CAGR of 8.63%, reaching the market size of US$2,096.655 million by the year 2027. The global glycomics market is anticipated to propel at … [Read more…]

Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by GN Corporation

Hyperthermia system made in Japan, benefitting cancer patients, attracts the interest of overseas cancer hospitals. TOKYO–(BUSINESS WIRE)–Treatment of cancer using one’s own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional chemotherapy, radiotherapy and surgery, practiced in Japan for long is now offered in Vinmec … [Read more…]

Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

TOTUM•070 demonstrates excellent results in volunteers with blood LDL cholesterol levels above 130 mg/dl at randomization, its commercially targeted population and the primary subpopulation of the HEART study: Increased and lasting efficacy on blood LDL cholesterol levels, with a reduction of 13.7% after three months and 14.3% after six months, compared to placebo. A very … [Read more…]

Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)

Completion of preclinical studies support potential to advance PXL770 into Phase 2 development for ADPKD Compelling preclinical efficacy data confirm strategic focus for PXL770 in rare metabolic diseases LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis … [Read more…]

LEO Pharma Launches AD Days Around the World Campaign to Raise Awareness of the Impact of Atopic Dermatitis Across Cultures

In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases … [Read more…]